2023-504602-11-00招募中3 期
Effects of Dopaminergic Therapy in Patients with Alzheimer's Disease: A 24 weeks prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate Alzheimer's disease patients.
Fondazione Santa Lucia IRCCS21 个研究点 分布在 4 个国家目标入组 378 人开始时间: 2023年9月18日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 378
- 试验地点
- 21
- 主要终点
- ● to evaluate efficacy of rotigotine in combination with rivastigmine on frontal lobe cognitive functions as compared to rivastigmine in combination with placebo (change from Baseline to Week 24 in the FAB);
研究概览
简要总结
To evaluate efficacy of rotigotine in combination with rivastigmine on frontal lobe cognitive functions as compared to rivastigmine in combination with placebo (change from Baseline to Week 24 in the FAB);
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Men and women (non-childbearing potential, as defined in Appendix 2) with a diagnosis of AD according to IWG criteria
- •Age 50-85 years
- •MRI or computerized tomography (CT) assessment within twelve months before baseline, corroborating the clinical diagnosis of AD and excluding other potential causes of dementia, especially cerebrovascular lesions (see exclusion criteria, number 3)
- •Patients who show CSF biomarker data supporting the diagnosis of AD measured within the last 3 years, or patients with a positive Amyloid Pet Scan within the last 3 years will qualify for the study
- •Mild to moderate stage of AD according to MMSE ≥18 and ≤26
- •Clinical Dementia Rating (CDR) total score of 0.5 or 1 (mild)
- •Evidence of frontal lobe dysfunctions as assessed by FAB ≤14
- •Absence of major depressive disease according to GDS of < 5
- •Formal education for eight or more years
- •Previous decline in cognition for more than six months as documented in patient medical records
- •A caregiver available and living in the same household or interacting with the patient and available if necessary to assure administration of drug
- •Patients living at home or nursing home setting without continuous nursing care
- •General health status acceptable for a participation in a 6-month clinical trial
- •Stable pharmacological treatment of any other chronic condition for at least one month prior to screening
- •No regular intake of prohibited medications.
- •Signed informed consent by the patient, prior to the initiation of any study specific procedure and signed consent of the caregiver
排除标准
- •Failure to perform screening or baseline examinations
- •Hospitalization or change of chronic concomitant medication one month prior to screening or during screening period
- •Clinical, laboratory or neuro-imaging findings consistent with: • other primary degenerative dementia (dementia with Lewy bodies, fronto-temporal dementia, Huntington’s disease, Creutzfeldt-Jakob Disease, Down’s syndrome, etc.); • other neurodegenerative condition (Parkinson’s disease, amyotrophic lateral sclerosis, etc.); • orthostatic hypotension and autonomic disorders • cerebrovascular disease (major infarct, one strategic or multiple lacunar infarcts, extensive white matter lesions > one quarter of the total white matter); • other central nervous system diseases (severe head trauma, tumors, subdural hematoma or other space occupying processes, etc.); • seizure disorder; • other infectious, metabolic, or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.).
- •A current DSM-V diagnosis of active major depression, schizophrenia, or bipolar disorder
- •Clinically significant, advanced, or unstable disease that may interfere with primary or secondary variable evaluations, and which may bias the assessment of the clinical or mental status of the patient or put the patient at special risk, such as: • chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, Gamma GT, alkaline phosphatase > 2.5 ULN); • respiratory insufficiency; • renal insufficiency (serum creatinine >2 mg/dl) or creatinine clearance ≤ 30 mL/min according to Cockcroft-Gault formula). In case of creatinine clearance ≤30 mL/min, an alternative verification of the renal function must be completed using Cystatin C analysis. In case of normal level of Cystatin C, the patient can be included; • heart disease (myocardial infarction, unstable angina, heart failure, Cardiomyopathy within six months before screening); • bradycardia (heart beat <50/min.) or tachycardia (heart beat >95/min); • hypertension (>180/95) or hypotension (<90/60) requiring treatment with more than three drugs; •AV block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcB-interval (males >450 and females >470 msec); • uncontrolled diabetes defined by HbA1c >8.5;
结局指标
主要结局
● to evaluate efficacy of rotigotine in combination with rivastigmine on frontal lobe cognitive functions as compared to rivastigmine in combination with placebo (change from Baseline to Week 24 in the FAB);
● to evaluate efficacy of rotigotine in combination with rivastigmine on frontal lobe cognitive functions as compared to rivastigmine in combination with placebo (change from Baseline to Week 24 in the FAB);
次要结局
未报告次要终点
研究者
Dr. Giacomo Koch
Scientific
Fondazione Santa Lucia IRCCS
研究点 (21)
Loading locations...
相似试验
尚未招募
3 期
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk MedulloblastomaNCT07291102Nationwide Children's Hospital96
招募中
3 期
Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB)2024-517133-40-00GPOH gGmbH46
招募中
3 期
THE EFFECT OF ROPINIROLE ON FUNCTIONAL CONNECTIVITY AND METACOGNITION IN HEALTHY SUBJECTS2025-520800-81-00Universita' Degli Studi Di Modena E Reggio Emilia20
招募中
4 期
CHOLINE-2 - Donepezil Versus Non-drug Treatment in Alzheimer's Disease2024-515038-34-00Assistance Publique Hopitaux De Paris240
已完成
1 期
AMEND - Add-on MEmaNtine to Dopamine modulation to improve negative symptoms at first psychosis2024-513878-21-02Region Hovedstadens Psykiatriske46